Florian Fitzal
A5019454470- Breast Cancer Treatment Studies
- Breast Implant and Reconstruction
- Advanced Breast Cancer Therapies
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Bone health and treatments
- Reconstructive Surgery and Microvascular Techniques
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Cancer Risks and Factors
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Computational Drug Discovery Methods
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
- Cancer survivorship and care
- Digital Imaging in Medicine
- Body Image and Dysmorphia Studies
- Lung Cancer Treatments and Mutations
- Global Cancer Incidence and Screening
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
Medical University of Vienna
2016-2025
Hanusch Hospital
2009-2025
Austrian Breast & Colorectal Cancer Study Group
2009-2025
Innsbruck Medical University
2016-2025
Comprehensive Cancer Center Vienna
2015-2024
U-M Rogel Cancer Center
2021
Comprehensive Blood & Cancer Center
2021
Vienna General Hospital
2006-2020
Krankenanstalt Rudolfstiftung der Stadt Wien
2020
Ordensklinikum Linz Barmherzige Schwestern
2014-2019
Ovarian suppression plus tamoxifen is a standard adjuvant treatment in premenopausal women with endocrine-responsive breast cancer. Aromatase inhibitors are superior to postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties.
According to current guidelines, molecular tests predicting the outcome of breast cancer patients can be used assist in making treatment decisions after consideration conventional markers. We developed and validated a gene expression signature likelihood distant recurrence with estrogen receptor (ER)-positive, HER2-negative treated adjuvant endocrine therapy.RNA levels assessed by quantitative reverse transcriptase PCR formalin-fixed, paraffin-embedded tumor tissue were calculate risk score...
Background: Conflicting evidence exists regarding the value of surgical resection primary in stage IV breast cancer patients. Objective: The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing surgery followed by systemic therapy to de novo cancer. Methods: Between 2011 and 2015, 90 previously untreated patients were randomly assigned tumor (Arm A) or B) Austria. Overall (OS) was defined as study endpoint. Results: stopped early due poor recruitment....
For postmenopausal women with hormone-receptor-positive breast cancer, the most effective duration for adjuvant therapy an aromatase inhibitor remains unclear.In this prospective, phase 3 trial, we randomly assigned cancer who had received 5 years of endocrine to receive anastrozole additional 2 (2-year group, receiving a total 7 years) or (5-year 10 years). The primary end point was disease-free survival. analysis included all patients were still participating in trial and no recurrence...
The 18th St Gallen International Breast Cancer Conference held in March 2023, Vienna, Austria, assessed significant new findings for local and systemic therapies early breast cancer with a focus on the evaluation of multimodal treatment options. emergence more effective, innovative agents both preoperative (primary or neoadjuvant) post-operative (adjuvant) settings has underscored pivotal role multidisciplinary approach decision making, particularly when selecting therapy an individual...
Importance Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from positive to negative neoadjuvant chemotherapy are sparse. Additionally, the best surgical staging technique this scenario is unknown. Objective To investigate sentinel biopsy (SLNB) dual-tracer mapping or targeted (TAD), which combines SLNB localization and retrieval clipped node. Design, Setting, Participants In multicenter retrospective cohort...
Complete lymph node removal through conventional axillary dissection (ALND) has been standard treatment for breast cancer patients almost a century. In the 1990s, however, and in parallel with advent of sentinel (SLN) procedure, ALND came under increasing scrutiny due to its association significant patient morbidity. Several studies have since provided evidence suggest omission ALND, often favor radiation, selected clinically node-negative, SLN-positive patients, thus supporting current...
Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications post-mastectomy radiation therapy (PMRT) have broadened. The aim of Oncoplastic Breast Consortium initiative was to address relevant questions arising this clinically challenging scenario.A large global panel oncologic, oncoplastic reconstructive surgeons, patient advocates oncologists developed recommendations clinical practice in an iterative...
To develop a 3.0 Tesla breast imaging protocol that combines high temporal and spatial resolution three-dimensional MR sequences for quantitative time course morphologic analysis of lesions.Thirty-four patients were included in the study (age range, 31-82; mean age, 54.3). The was approved by Institutional Review Board written informed consent obtained from all patients. magnetic resonance included: coronal T1-weighted volume-interpolated-breathhold-examination sequence, focused on optimal...
Purpose Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor–positive breast cancer. The ABCSG-8 (Austrian Breast and Colorectal Cancer Study Group 8) study is a large phase III clinical trial addressing the sequence strategy containing ANA comparison 5 years of TAM low- to intermediate-risk group patients. Patients Methods Endocrine patients G1 or G2 tumors were eligible. After...
Brain metastases (BM) are frequently diagnosed in patients with HER-2-positive metastatic breast cancer; addition, an increasing incidence was reported for triple-negative tumours. We aimed to compare brain free survival (BMFS) of cancer subtypes treated between 1996 until 2010. measured as the interval from diagnosis extracranial BM. HER-2 status analysed by immunohistochemistry and reanalysed fluorescent situ hybridisation if a score 2+ gained. Oestrogen-receptor (ER) progesterone-receptor...
The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer postmenopausal women. In addition, we examined EP may help tailor therapy these patients. From January 1996 June 2004, 3714 patients were randomly assigned either tamoxifen or followed by anastrozole within the prospective ABCSG 8 trial. Using assay scores from EP, classified tumour blocks as...
Prognostic molecular assays may aid in treatment decisions for women with estrogen receptor (ER)-positive, HER2-negative breast cancer. The prognostic value of a 12-gene expression assay (EndoPredict) was reevaluated the combined ABCSG-6/8 cohorts longer clinical follow-up.EndoPredict (EP; score, EPclin score) evaluated ER-positive, node-positive and node-negative cancer who received 5 years endocrine therapy only (median follow-up, 9.6 years; N = 1,702). Distant recurrence-free rate (DRFR;...